Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S253130, C544S364000, C544S365000, C544S131000, C544S383000, C544S393000, C546S233000, C546S234000, C546S276400, C546S277400, C546S284100, C548S309700, C564S185000
Reexamination Certificate
active
08008305
ABSTRACT:
The invention relates to a compound of formulawhereinR1, R2, X, L, W, n, and o are defined herein andto pharmaceutically suitable acid addition salts thereof, with the exception of the following compounds6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide (CAS 199478-31-4),N-(3,4-dichloro-benzyl)-3-fluoro-benzamide (CAS 424815-98-5),N-(4-chloro-benzyl)-3-fluoro-benzamide (CAS 544661-83-8),N-(3-chloro-benzyl)-3-fluoro-benzamide (CAS 796051-07-5), andN-phenethyl-6-phenylamino-nicotinamide (CAS 571913-74-1).The compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of CNS disorders.
REFERENCES:
patent: 2161938 (1939-06-01), Sonn
patent: 2457047 (1948-12-01), Kyrides
patent: 2731471 (1956-01-01), Synerholm et al.
patent: 2744909 (1956-05-01), Speeter
patent: 2744910 (1956-05-01), Speeter
patent: 2778836 (1957-01-01), Morren
patent: 2919274 (1959-12-01), Faust et al.
patent: 3161653 (1964-12-01), Fruhstorfer et al.
patent: 3354175 (1967-11-01), Fruhstorfer et al.
patent: 3377247 (1968-04-01), Elbe
patent: 3480630 (1969-11-01), Stahle et al.
patent: 3586695 (1971-06-01), Wysong et al.
patent: 3622579 (1971-11-01), Stahle et al.
patent: 3660423 (1972-05-01), Wysong et al.
patent: 3758476 (1973-09-01), Rippel et al.
patent: 3818035 (1974-06-01), Binon et al.
patent: 3818094 (1974-06-01), Stahle et al.
patent: 3992403 (1976-11-01), Roebke
patent: 4125620 (1978-11-01), Stahle et al.
patent: 4146647 (1979-03-01), Lafon
patent: 4323570 (1982-04-01), Stenzel et al.
patent: 4665095 (1987-05-01), Winn et al.
patent: 4734419 (1988-03-01), Hashimoto et al.
patent: 5610174 (1997-03-01), Craig et al.
patent: 5658938 (1997-08-01), Geerts et al.
patent: 5866583 (1999-02-01), Guerry et al.
patent: 2002/0019390 (2002-02-01), Wong et al.
patent: 2003/0181354 (2003-09-01), Abdulrazik
patent: 2003/0236259 (2003-12-01), Hohlweg et al.
patent: 2003/0236274 (2003-12-01), Tasaka et al.
patent: 2006/0189626 (2006-08-01), Hoffmann et al.
patent: 2007/0249579 (2007-10-01), Wang et al.
patent: 2246027 (2000-02-01), None
patent: 1695005 (1971-02-01), None
patent: 3133887 (1983-03-01), None
patent: 0 024 829 (1981-03-01), None
patent: 0086043 (1983-08-01), None
patent: 0 125 410 (1984-11-01), None
patent: 0 166 937 (1986-01-01), None
patent: 0 331 374 (1989-09-01), None
patent: 0 424 059 (1991-04-01), None
patent: 0 857 483 (1998-08-01), None
patent: 0 924 209 (1999-06-01), None
patent: 1 103 243 (2001-05-01), None
patent: 1 413 576 (2004-04-01), None
patent: 1449841 (2004-08-01), None
patent: 1669348 (2006-06-01), None
patent: 323 985 (1966-12-01), None
patent: 6 551 (1968-12-01), None
patent: 877306 (1961-09-01), None
patent: 1016514 (1966-01-01), None
patent: WO 96/22768 (1996-08-01), None
patent: WO 97/12874 (1997-04-01), None
patent: WO 98/12183 (1998-03-01), None
patent: WO 01/30762 (2001-05-01), None
patent: WO 01/81334 (2001-11-01), None
patent: WO 02/22801 (2002-03-01), None
patent: WO 02/40453 (2002-05-01), None
patent: WO 02/076950 (2002-10-01), None
patent: WO 03/092374 (2003-11-01), None
patent: WO 2004/014898 (2004-02-01), None
patent: WO 2006/014168 (2006-02-01), None
patent: WO 2006/107923 (2006-10-01), None
patent: WO 2006/119411 (2006-11-01), None
patent: WO 2007/024944 (2007-03-01), None
patent: WO 2007/071358 (2007-06-01), None
patent: WO 2007/098352 (2007-08-01), None
Deutch et al., (1999) Neurotransmitters. In Fundamental Neuroscience (2nded.) pp. 193-234, Academic Press.
Wong, et al., (2001) Nat. Rev. Neurosci. 2, pp. 343-351.
Carlsson. et al. (2001) Annu Rev. Pharmacol. Toxicol. 41, pp. 237-260.
Tuite et al., (2003) Expert Opin. Investig. Drugs 12, pp. 1335-1352.
Castellanos et al., (2002) Nat. Rev. Neurosci. 3, pp. 617-628.
Usdin, E.; Sandler, M.; Editors. Psychopharmacology Series, vol. 1: Trace Amines and the Brain. [Proceedings of a Study Group at the 14th Annual Meeting of the American College of Neuropsychoparmacology, San Juan, Puerto Rico](1976), pp. 1-281.
Lindemann et al., (2005) Trends in Pharmacol. Sci. 26, pp. 274-281.
Branchek et al., (2003) Curr. Opin. Pharmacol. 3, pp. 90-97.
Premont et al. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, pp. 9474-9475.
Mousseau et al., (1995) Prog. Brain Res. 106, pp. 285-291.
McCormack et al. (1986) J. Neurosci. 6, pp. 94-101.
Dyck, L. E. (1989) Life Sci. 44, pp. 1149-1156.
Parker, et al. (1988) J. Pharmacol. Exp. Ther. 245, pp. 199-210.
Lindemann et al. (2005) Genomics 85, pp. 372-385.
Moormann, et al., (1990) J. Med. Chem. pp. 614-626.
Hlasta et al., (1987) vol. 30, J. Med. Chem. pp. 1555-1562.
Dash et al., (2006) J. Heterocyclic Chem. pp. 401-404.
Gentili et al., (2004) J. Med. Chem. vol. 47 pp. 6160-6173.
Dias et al. (2005) J. Med. Chem. vol. 40 pp. 1206-1213.
Pigini et al., (1987) Eur. J. Med. Chem. vol. 22 pp. 273-276.
Wu et al., Synthesis (2003) pp. 1657-1660.
Fujioka et al., (2005) Tetrahedron Lett. vol. 46, pp. 2197-2199.
Ishihara et al., Synlett (2006) pp. 227-230.
Pinza et al. (1976) Heterocycles, vol. 4 pp. 1699-1706.
Kornicka et al. (2006) Heterocycles vol. 68 pp. 687-699.
Kosasayama et al., (1979) Chem. Pharm. Bull. vol. 27 pp. 831-840.
Lloyd et al., (1980) Tetrahedron vol. 36, pp. 2675-2679.
Flippin et al., Tetrahedron Letters, vol. 34, pp. 3255-3258 (1993).
Liebigs, Ann. Chem. pp. 2061-2071 (1980), Bestmann et al.
Huh et al., Tetrahedron, vol. 58, pp. 9925-9932 (2002).
Huh et al., Tetrahedron, vol. 60, pp. 9857-9862 (2004).
Law et al., J. Med. Chem. vol. 41, pp. 2243-2251 (1998).
Debernardis et al., J. Med. Chem. vol. 29, pp. 1413-1417 (1986).
Mohammadpoor-Baltork, Bull. Korean Chem. Soc. vol. 24, p. 1354-1356 (2003).
Abdollahi-Alibeik et al., Bioorg. Med. Chem. Lett. vol. 14, pp. 6079-6082 (2004).
Amemiya, Synth. Commun. vol. 20, pp. 2483-2489 (1990).
Ohta, Chem. Pharm. Bull. vol. 35, pp. 1058-1069 (1987).
Olah, Synlett pp. 647-650 (1992).
Katz et al., Tetrahedron, vol. 45, pp. 1801-1814 (1989).
Wentland et al., J. Med. Chem. vol. 30, pp. 1482-1489 (1987).
Campos et al., Heterocycles, vol. 40, p. 841-849 (1995).
Ohta, Synthesis, pp. 78-81 (1990).
Mancuso et al., J. Org. Chem. vol. 43, pp. 2480-2482 (1978).
Mohammadpoor-Baltork, Synlett, pp. 2803-2805 (2004).
Cahiez et al., Synthesis, pp. 2138-2144 (1999).
Evans et al., Tetrahedron Lett. vol. 39, pp. 2937-2940 (1998).
Nakamura et al., J. Chem. Soc. Perkin Trans. 1, pp. 1061-1066 (2002).
Turner, et al. (1991) J. Org. Chem. vol. 56, pp. 5739-5740.
Zhang et al., J. Med. Chem. 1997, 40, pp. 3014-3024.
Reimann et al., Arch. Pharm. 1989, vol. 322, pp. 363-367.
Klapars, et al., J. Am. Chem. Soc. 2001, vol. 123, pp. 7727-7729.
Anderson, et al., Tetrahedron, 2002, vol. 58, pp. 8475-8481.
Touzeau et al., J. Med. Chem. 2003, vol. 46, pp. 1962-1979.
Altenbach et al., Synthesis and Structure-Activity Studies onN-[5-(1H-Imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an Imidasole-Containing α1A-Adrenoceptor Agonist, J. Med. Chem. (2004), 47: 3220-3235.
Amemiya et al., Synthesis and α-Adrenergic Activities of 2-and 4-Substituted Imidazoline and Imidazoline Analogues, J. Med. Chem. (1992), 35:750-755.
Bagley et al., Synthesis and α2-Adrenegeric Activities of Imidazole and Imidazolidine Analogues: In Vitro and In Vivo Selectivity, Medicinal Chemistry Research (1994), 4:346-364.
Branchek et al., Trace amine receptors as targets for novel therapeutics: legend, myth and fact, Curr. Opin. Phamacol. (2003), 3:90-97.
Bunzow et al., Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor, Molecular Pharmacology (2001), 60: 1181-1188.
Carroll et al., In Vitro and In Vivo Characterization of Alpha-1A Selective Agonists and Their Utility for Stress Incontinence, Med. Chem. Res. (2004), 13:134-148.
De Bernardis et al., Conformationally Defined Adregernic Agents. 5. Resolution, Absolute Configuration, and Pharmacological Characterization of the Enantiomers of 2-(5,6-Dihydroxy-1,2,3,4-tetrahydro-l-naphthyl)imidazoline: A Potent Agonist at a α—Adren
Galley Guido
Groebke Zbinden Katrin
Norcross Roger
Stalder Henri
Bernhardt Emily
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
TAAR1 ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TAAR1 ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TAAR1 ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2780464